Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A second phase 3 trial of Levosimendan in Pulmonary Hypertension Patients With Heart Failure With Preserved Left Ventricular Ejection Fraction (PH-HFpEF)

Trial Profile

A second phase 3 trial of Levosimendan in Pulmonary Hypertension Patients With Heart Failure With Preserved Left Ventricular Ejection Fraction (PH-HFpEF)

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 26 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Levosimendan (Primary)
  • Indications Heart failure; Pulmonary hypertension
  • Focus Registrational; Therapeutic Use
  • Acronyms LEVEL-2
  • Sponsors Tenax Therapeutics
  • Most Recent Events

    • 25 Mar 2025 According to a Tenax Therapeutics media release, Company updated Phase 3 development plan for TNX-103 (oral levosimendan). The plan includes an amendment to expand enrollment and enhance the statistical power of the ongoing Phase 3 LEVEL study, as well as the protocol for LEVEL-2, companies second registrational Phase 3 study.
    • 05 Mar 2025 According to a Tenax Therapeutics media release, two registrational studies (LEVEL and LEVEL-1) will satisfy the requirements, including the safety data expectations, to file in the U.S. and other geographies.
    • 05 Mar 2025 According to a Tenax Therapeutics media release, U.S. Food and Drug Administration (FDA) has completed their review of this trial and company received input from the FDA on the protocol for the LEVEL-2 study, and agreement by FDA to initiate this second global trial and company will be commencing study later this year, in several countries with first patient expected to be enrolled this year.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top